文献速递消化系统肿瘤

贝特类联合他汀降低肝细胞癌风险的回顾性队列研究

Reduced risk of hepatocellular carcinoma in the use of fibrate as an add-on to statin: A retrospective population-based cohort study.
PubMed 文献 · Eur J Cancer · 2025-11-01

该研究基于韩国国民健康保险服务2010至2019年数据,比较他汀单药与贝特类联合他汀治疗血脂异常患者的肝细胞癌发生率。共分析789,958例匹配个体,联合治疗组肝细胞癌风险显著低于他汀单药组(调整HR 0.74,95%CI 0.67-0.83),且随贝特类使用时间延长风险进一步降低。

要点

  • 贝特类联合他汀与肝细胞癌风险降低相关,调整HR为0.74。
  • 贝特类使用超过1年者风险降低更明显,调整HR为0.71。
  • 该回顾性队列结果需前瞻性研究进一步验证。

核心结论

  • 贝特类作为他汀的附加治疗与肝细胞癌风险降低相关。

研究设计与样本

  • 基于韩国国民健康保险服务2010至2019年的回顾性人群队列研究。
  • 按年龄、性别和高甘油三酯血症匹配他汀单药组与贝特类联合他汀组各394,979例。

主要发现

  • 他汀组随访1,644,037.6人年发生791例肝细胞癌,联合组随访1,646,939.6人年发生703例。
  • 肝细胞癌发病率在他汀组和联合组分别为每1000人年0.48和0.43。
  • 未调整模型HR为0.89(95%CI 0.80-0.98),调整模型aHR为0.74(95%CI 0.67-0.83)。
  • 贝特类使用不足1年者aHR为0.76(95%CI 0.68-0.86),超过1年者aHR为0.71(95%CI 0.61-0.82)。

临床怎么用

  • 对于血脂异常患者,在贝特类联合他汀治疗时可关注肝细胞癌风险降低的潜在获益。

局限性

  • 回顾性队列设计可能残留混杂。
  • 作者指出需前瞻性研究阐明贝特类对肝细胞癌风险的作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This study investigated the reduced risk of hepatocellular carcinoma (HCC) by the use of fibrates as an add-on to statins. METHODS: This population-based cohort study was conducted from the Korean National Health Insurance Service from 2010 to 2019 in Korea. We compared the incidence of HCC between statin users and those taking fibrates and statins for dyslipidemia, matched using age, sex, and hypertriglyceridemia. RESULTS: We analysed 789,958 individuals, including 394,979 statin users and 394,979 who were matched users of combined fibrate-statin therapy. During the 1644,037.6 person-years of follow-up, 791 HCC cases were observed in the statin group, whereas 703 HCC cases were observed in the fibrate-statin group during 1646,939.6 person-years of follow-up. The HCC incidence rates per 1000 person-years were 0.48 and 0.43 in the statin and fibrate-statin groups, respectively. The risk of HCC was lower in the fibrate-statin group compared to the statin-only group in the unadjusted and adjusted models (hazard ratio [HR] 0.89 with 95 % confidence interval [CI]: 0.80-0.98 and adjusted HR [aHR] 0.74 with 95 % CI: 0.67-0.83). The reduction of HCC development by fibrate-statin increased as the duration of fibrate administration lengthened (aHR 0.76 with 95 % CI: 0.68-0.86 in the use of fibrate and statin for <1 year; and aHR 0.71 with 95 % CI: 0.61-0.82 for >1 year). CONCLUSIONS: Fibrates as an add-on to statin were associated with a reduced risk of HCC compared to statins. Further prospective studies are needed to clarify the role of fibrate on the risk of HCC.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Sohn W, Hong S, Han K, et al. Reduced risk of hepatocellular carcinoma in the use of fibrate as an add-on to statin: A retrospective population-based cohort study. Eur J Cancer. 2025. PMID: 41205257. doi:10.1016/j.ejca.2025.116094

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。